✦ LIBER ✦

Exemestane as Adjuvant Treatment of Early Breast Cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter Trials

✍ Scribed by Stephen E. Jones

Book ID: 119934761
Publisher: CIG Media Group, LP.
Year: 2006
Tongue: English
Weight: 87 KB
Volume: 6
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2006.s.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant tamoxifen and exemestane in ear

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

✍ Cornelis JH van de Velde; Daniel Rea; Caroline Seynaeve; Hein Putter; Annette Ha 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 321 KB

Quality of life in relation to tamoxifen

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study

✍ J. G. H. van Nes, D. B. Y. Fontein, E. T. M. Hille, D. W. Voskuil, F. E. van Lee 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 272 KB

Endometrial effects of exemestane compar

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy

✍ D.G. Kieback; N. Harbeck; W. Bauer; P. Hadji; G. Weyer; T. Menschik; A. Hasenbur 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 346 KB

Survival and safety of exemestane versus

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

✍ RC Coombes; LS Kilburn; CF Snowdon; R Paridaens; RE Coleman; SE Jones; J Jassem; 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 314 KB

Survival and safety of exemestane versus

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

✍ RC Coombes; LS Kilburn; CF Snowdon; R Paridaens; RE Coleman; SE Jones; J Jassem; 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 314 KB

## Background: Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer. however, little information exists on the long-term effects

Cost-effectiveness of exemestane versus

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3

✍ Jonas Lundkvist; Nils Wilking; Stig Holmberg; Linus Jönsson 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 368 KB